SecBot SecBot
SECBOTREPLAY Home › Report › PMN

PMN · Q3 net loss $8.2M, cash $44.1M

ProMIS Neurosciences Inc. · 8-K filed Nov 12, 2026 at 16:17 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 12, 2026 at 16:17 ET

ProMIS Neurosciences reported Q3 2026 net loss of $8.2M ($0.89 per share) and cash of $44.1M, reaffirming on-track unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in Q1 2027. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech with no consensus EPS or revenue to compare against.

  • Cash of $44.1M as of September 30, 2026, expected to fund operations through 2027
  • Net loss of $8.2M for Q3 2026 versus $11.6M in Q3 2025
  • R&D expenses decreased 32% to $6.7M due to PRECISE-AD nearing completion
  • PRECISE-AD unblinded 12-month topline data anticipated in Q1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access